Nozin

What Nozin does

Nozin (legal entity: Global Life Technologies Corp.) is a Bethesda, Maryland-based, privately held specialty medical-products company founded in the early 2000s that manufactures and sells an alcohol-based nasal antiseptic under the Nozin brand. The core product, Nozin Nasal Sanitizer, is built on the patented Nozaseptin formula — 62% ethyl alcohol combined with jojoba, vitamin E, orange oil, lauric acid, and benzalkonium chloride — designed for topical application to the nasal vestibule (anterior nares), the primary reservoir for microbial colonization. The product is offered in a reusable 12mL bottle for individual use and in single-use Popswab ampules (10-count and 250-count bulk) for healthcare facilities, with the Popswab delivery system itself separately patented.

The company operates a dual-channel business model. On the consumer side, Nozin sells direct-to-consumer through its own e-commerce store (Nozin.com) and Amazon Marketplace at price points of $24 (12mL bottle), $32 (10-count ampules), and $779 (250-count bulk). On the healthcare side, the company sells the Nozin NOVA program suite — a subscription/recurring-service offering that bundles the antiseptic with site-specific analysis, customized implementation strategies, and ongoing consulting support to hospitals, ICUs, and surgical centers. Enterprise sales are executed through a dedicated U.S. field organization with Regional Vice Presidents covering five regions plus a Director of Sales for the Southeast.

The customer base spans hospitals and surgical centers implementing HAI/SSI prevention bundles (primary), ICUs and critical care units running universal decolonization protocols, individual health-conscious consumers, healthcare workers, athletes and sports teams, and workplace health-and-safety programs across employers in hospitality, manufacturing, transportation, and education. The product is supported by a substantial clinical-evidence base with peer-reviewed studies demonstrating outcomes such as an 88.33% decrease in isolation days, a 56.6% reduction in CLABSI SIRs, and a 41.3% reduction in SSIs in elective total joint arthroplasty. Eight U.S. patents protect the formula and delivery system, and strategic partnerships with The Leapfrog Group and APIC anchor the company's positioning in the patient-safety and infection-prevention professional communities.

Name

Nozin

Legal name

Global Life Technologies Corp.

Website

https://nozin.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Nozin (Global Life Technologies Corp.) is a Bethesda, MD-based specialty medical-products company that sells a patented 62% alcohol-based nasal antiseptic (Nozin Nasal Sanitizer) and the Popswab single-use ampule system to hospitals, ICUs, surgical centers, and individual consumers for nasal decolonization and infection prevention.

Ownership category

akta.pro rank

Product category

Antiseptic Nasal Decolonization Products

NAICS

Soap, Cleaning Compound, and Toilet Preparation Manufacturing (3256)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays) (CRADAMAG)

akta.pro secondary industry

Eye, Ear & Nasal Care (HLAIADAF)

Keywords

• Nasal decolonization
• Antiseptic nasal products
• Infection prevention programs
• Healthcare antiseptic solutions
• Topical nasal sanitizer

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Consumer Product Sales: Direct-to-consumer sales of Nozin Nasal Sanitizer products including 12mL bottles ($24), Popswab ampules 10-count ($32), and Popswab ampules 250-count ($779). One-time purchase model through e-commerce.
2. Healthcare Facility Programs: B2B sales of nasal decolonization programs to hospitals and healthcare facilities. Nozin NOVA programs provide proprietary analytical tools, consulting services, and ongoing support for implementation of universal nasal decolonization protocols.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Nozin manufactures and sells over-the-counter alcohol-based nasal antiseptic products (Nozin® Nasal Sanitizer® in 12mL bottles and Popswab® single-use ampules) formulated with the patented Nozaseptin® formula (62% ethyl alcohol combined with jojoba, vitamin E, and orange oil) to reduce nasal bacteria carriage and infection risk. The company complements its consumer product line with Nozin NOVA℠ Programs, a B2B suite of nasal decolonization protocols, analytical tools, and consulting services for hospitals, ICUs, surgical centers, and workplace health programs.

Product overview

Nozin offers a focused product portfolio centered on nasal decolonization through its Nozin® Nasal Sanitizer® antiseptic line. The core offerings include the 12mL bottle (for personal/daily use with reusable cotton swabs) and Popswab® ampules in 10-count and 250-count packages (for healthcare facility use with single-use delivery). All products utilize the patented Nozaseptin® formula combining 62% ethanol with natural emollients. The products are complemented by the Nozin NOVA℠ Programs, a proprietary suite of analytical tools and consulting services designed to help healthcare facilities implement and optimize nasal decolonization protocols for infection prevention.

Differentiator

Problem solved

Functional benefit

Brands

• Nozin® Allergy Master®: Product line for allergy relief, part of Global Life Technologies Corp. product portfolio.

Products and services

• Nozin® Nasal Sanitizer® 12mL Bottle Over-the-counter alcohol-based (62% ethyl alcohol) topical antiseptic nasal product with the patented Nozaseptin® formula combining ethanol with antioxidant-rich natural emollients (jojoba, vitamin E). Applied to the skin at the nasal vestibule with a cotton swab to reduce nasal bacteria carriage and risk of infection; targeted at individual consumers and personal use.
• Nozin® Nasal Sanitizer® Popswab® Ampules 10 ct Pre-filled single-use ampules of the Nozin® Nasal Sanitizer® antiseptic delivered via the proprietary Popswab® crushable-ampule delivery system. Provides convenient, hygienic, pre-measured single-dose application to the nasal vestibule; designed for personal use and lighter clinical applications.
• Nozin® Nasal Sanitizer® Popswab® Ampules 250 ct Bulk packaging of 250 pre-filled single-use Popswab® ampules of Nozin® Nasal Sanitizer® antiseptic. Designed for healthcare facility use and daily decolonization protocols supporting ICU, surgical, and workplace health programs.
• Nozin NOVA℠ Programs Proprietary suite of nasal colonization risk mitigation programs for healthcare facilities (hospitals, ICUs, surgical centers). Includes comprehensive evaluation, proprietary analytical tools, customized implementation strategies, and ongoing consultant-guided support to deploy universal nasal decolonization protocols using Nozin® Nasal Sanitizer® antiseptic.

Quantifiable outcome

• 88.33% decrease in isolation days and $430,604 net cost savings over 10 months at 7 network hospitals
• +5 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• The Leapfrog GroupcoreStrategic or Co-development PartnerNozin announced partnership with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on healthcare safety. CEO John Willimann sits on the Leapfrog Partners Advisory Committee. The partnership aims to expand awareness of daily nasal decolonization as an essential patient safety measure. The Leapfrog Group was founded in 2000 and sets standards for hospitals and ASCs on quality of care.
• APIC (Association for Professionals in Infection Control and Epidemiology)coreStrategic or Co-development PartnerNozin is an APIC Strategic Partner. APIC is the association for professionals in infection prevention and control. Strategic partnership supports Nozin's positioning as a leader in nasal decolonization and infection prevention.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• 3M: 3M Health Care sells 3M Skin and Nasal Antiseptic (povidone-iodine) for preoperative nasal decolonization, competing directly with Nozin's alcohol-based approach in the same hospital and surgical center channel.
• NeilMed Pharmaceuticals: NeilMed is the leading consumer nasal hygiene brand (saline sprays, neti pots, sinus rinses) sold through mass retail and e-commerce, directly competing with Nozin's consumer nasal product offering on Amazon and DTC channels.
• PDI (Professional Disposables International): PDI manufactures antiseptic skin and nasal prep products (Prevantics, Chlorascrub) used by hospitals and surgery centers for infection prevention, directly overlapping with Nozin's nasal decolonization and broader antiseptic positioning.
• GlaxoSmithKline (Bactroban): GSK markets Bactroban (mupirocin) nasal ointment, the incumbent antibiotic-based nasal decolonization therapy that Nozin explicitly positions against in its value proposition. Direct therapeutic substitute for the same clinical use case.

Broad incumbents

• Stryker: Stryker acquired Sage Products, which markets 2% chlorhexidine gluconate cloths and other preoperative skin prep products used in SSI prevention bundles alongside or in place of nasal decolonization. A broad healthcare incumbent competing for the same infection prevention wallet share.
• Medline: Medline is one of the largest privately held medical supply manufacturers and distributors, offering nasal antiseptic products, skin preps, and broader infection prevention consumables through GPO contracts to the same hospital channel as Nozin.
• Mölnlycke Health Care: Mölnlycke manufactures chlorhexidine-based antiseptic products (Hibiclens, Hibiscrub) widely used for surgical site infection prevention, including nasal antisepsis, giving it overlapping capabilities with Nozin and broader infection prevention presence.
• Becton Dickinson (BD): BD's Medication Management and Medical Surgery segments include skin antisepsis and infection prevention products sold to the same hospital channel as Nozin, though as part of a much broader medical device portfolio.
• Clorox Healthcare: Clorox Healthcare sells bleach-based disinfectants and antiseptic wipes used in healthcare facilities for infection prevention, including in conjunction with nasal decolonization protocols, providing overlapping end-customer relationships with broader portfolio offerings.

Emerging players

• Xlear: Xlear markets xylitol-based nasal sprays for sinus and nasal hygiene, positioned for daily consumer use in infection prevention contexts. Direct overlap with Nozin's DTC consumer positioning, though with a different active ingredient.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nozin

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nozin